High blood pressure, or hypertension, is one of the most common health issues worldwide. Often, it causes damage silently, showing no obvious warning signs until serious problems develop.
Recent animal research indicates that targeting inflammation more precisely might one day help lower blood pressure and repair some of the damage caused by hypertension.
Hypertension occurs when blood exerts excessive force against artery walls over extended periods. This increased pressure forces the heart to work harder and can gradually harm blood vessels, kidneys, the brain, and other organs.
Current treatments include a variety of effective medications that lower blood pressure through different mechanisms—such as removing excess salt and water, relaxing blood vessels, or blocking hormones and nerve signals that increase pressure.
Two bodily systems play key roles in regulating blood pressure: one involves nerves preparing the body for action, and the other uses hormones to control salt and fluid levels.
Scientists are now paying closer attention to another potential factor—long-term inflammation. Normally part of the body’s defense and repair systems, chronic inflammation can lead to tissue damage if it persists.
A recent study tested a drug called Compound17b, or Cmpd17b, which aims to influence inflammation without broadly suppressing the immune system. Instead, it targets switches on specific cells involved in inflammation and healing.
These switches, known as formyl peptide receptors, are present on immune cells, as well as cells in the heart and kidneys. They may help transition the body from an inflamed state back to healing.
The researchers evaluated Cmpd17b in male mice with a form of high blood pressure driven mainly by overactive nerve signals. They also included mice with normal blood pressure to see if the drug would lower pressure when it wasn’t elevated.
The study involved 45 mice over 28 days, with continuous monitoring of blood pressure, heart rate, and activity levels. The drug lowered blood pressure by approximately 6 mm Hg in hypertensive mice and did not affect mice with normal pressure.
The blood pressure reduction occurred gradually, reaching its peak during their most active period, when blood pressure is naturally higher. Notably, the drug didn’t cause a sudden drop, which suggests a more natural regulation.
Beyond lowering blood pressure, the scientists examined whether the drug could repair existing damage caused by hypertension. Long-term high blood pressure often results in fibrosis, the buildup of stiff, scar-like tissue in organs and blood vessels, impairing normal function.
Cmpd17b reduced fibrotic tissue in the kidneys of hypertensive mice. It also lessened collagen deposits in the aorta—the body’s main artery—and in the heart’s left ventricle. The kidneys showed particularly impressive signs of healing.
This tissue repair is critical because hypertension and kidney disease often reinforce each other in a damaging cycle. The treatment also made arteries about 37% more flexible and reduced their wall thickness by roughly 22%. Healthy arteries need to stretch with each heartbeat, so decreased flexibility and increased stiffness can make controlling blood pressure more difficult and burden the heart.
However, the drug didn’t fully restore all aspects of heart and blood vessel function. It didn’t significantly improve how well the heart pumps or fix smaller blood vessels, indicating it’s not a complete solution for all hypertension effects.
While promising, it’s important to remember that this research involved mice. Animal studies help us understand potential mechanisms, but many promising drugs in animals fail in human trials due to safety or effectiveness issues.
The experiment also had limitations: only 45 male mice were tested over just four weeks. Human hypertension can last for decades and occurs across diverse populations with different ages, health conditions, and causes.
Therefore, these findings shouldn’t change current treatment strategies. Existing blood pressure medications and lifestyle modifications remain the best proven ways to prevent serious complications like heart attack, stroke, and kidney disease.
The innovative aspect of this research is its focus on inflammation. Instead of broadly suppressing the immune response, scientists are exploring ways to encourage the body’s natural healing processes to resolve harmful inflammation and restore tissue health.
If future studies confirm these results, medications targeting inflammation pathways could eventually supplement current blood pressure treatments. More extensive animal studies and carefully controlled human trials are needed first.
Published in the journal Communications Biology in 2026, this research presents early evidence that managing inflammation resolution might help lower high blood pressure and reduce associated tissue scarring.
Overall, a 6 mm Hg average pressure reduction and improvements in kidney and artery health are encouraging outcomes, especially since healthy mice didn’t experience unnecessary decreases in blood pressure.
Nonetheless, this is preliminary research; the small animal model cannot reliably predict safety or efficacy in humans. Further investigation is essential before any clinical recommendations can be made.
